Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

YUTIQ Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan

globenewswire.com
EYPT EyePoint Pharmaceuticals' YUTIQ, utilizing their DurasertT technology, is FDA-approved for chronic non-infectious uveitis and shows strong revenue growth. The drug's long-acting delivery and expanding market for intravitreal implants contribute to a positive outlook. ANIP ANI Pharmaceuticals strengthened its retina-focused business by acquiring royalty obligations on YUTIQ and ILUVIEN. This strategic move, following their acquisition of Alimera Sciences, positions them for growth in the ophthalmology market. ALOT Alimera Sciences acquired U.S. commercialization rights for YUTIQ in 2023, enhancing sales infrastructure. This has led to projections exceeding USD 100 million annually in combined revenues from ILUVIEN and YUTIQ, indicating positive market reception.

YUTIQ Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "YUTIQ Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering.

The YUTIQ market report also covers patents, pricing, regional variations, and competitive landscape, offering a SWOT analysis and insights into emerging therapies and market dynamics.

The report addresses critical questions about YUTIQ's therapy class, market positioning, clinical trials, cost-effectiveness, and competitive landscape to support strategic decision-making.

YUTIQ Drug Summary

YUTIQ is a non-bioerodible intravitreal implant, FDA-approved for treating chronic non-infectious uveitis in the eye's posterior segment. It utilizes EyePoint Pharmaceuticals' DurasertT technology for sustained-release, providing anti-inflammatory effects for 36 months. It aims to minimize interventions and improve visual acuity.

YUTIQ Recent Developments

In March 2025, ANI Pharmaceuticals acquired the 3.125% perpetual royalty obligation on YUTIQ and ILUVIEN net revenues from SWK Funding LLC for USD 17.25 million. This strengthened their retina-focused business following ANI's acquisition of Alimera Sciences in September 2024.

The YUTIQ market report highlights its use in approved indications like Diabetic macular edema and Uveitis and potential in Retinal vascular occlusion and Wet age-related macular degeneration. The report provides sales forecasts, market size analysis, and insights into regulatory milestones and other developments.

Key Factors Driving YUTIQ Growth

Increasing Prevalence of Non-Infectious Posterior Uveitis: YUTIQ is experiencing growth due to the rising incidence of uveitis, particularly the posterior segment, which can cause blindness if untreated. In the U.S., over 100,000 adults are affected. The global market for uveitis treatments is growing, valued at approximately USD 0.8 billion in 2022, and is expected to expand further with improved diagnosis rates and new therapies.

Long-Acting Drug Delivery Offering Clinical Advantages: YUTIQ provides continuous fluocinolone acetonide delivery for up to three years, reducing the need for frequent injections. Key advantages include continuous drug release, reduced treatment burden, and long-term inflammation control.

Strong Revenue Growth in Early Commercialization: YUTIQ has exhibited rapid revenue growth, with USD 28.3 million generated in 2022, a 67% increase from 2021. Quarterly revenue in Q1 2023 rose to USD 7.4 million, a 60% year-over-year increase.

Expanded Commercialization Through Alimera Sciences: Alimera Sciences acquired U.S. commercialization rights in 2023, enhancing sales infrastructure and outreach. This led to projections exceeding USD 100 million annually in combined revenues from ILUVIEN and YUTIQ.

Favorable Pricing and Reimbursement Dynamics: YUTIQ's implant, with an average price of USD 4,000-5,000 per unit, offers significant revenue opportunities. Even a 10% market penetration in the U.S. could yield USD 40-50 million annually.

Growing Market for Intravitreal Implants: The market for intravitreal drug delivery technologies in ophthalmology is expanding, with fluocinolone-based implants projected to generate USD 100-200 million in annual sales by 2024.

For more information about this report visit https://www.researchandmarkets.com/r/g7zy6n

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.